The imidazodiazepine, KRM-II-81: An example of a newly emerging generation of GABAkines for neurological and psychiatric disorders.

MLA

Witkin, Jeffrey M., et al. “The Imidazodiazepine, KRM-II-81: An Example of a Newly Emerging Generation of GABAkines for Neurological and Psychiatric Disorders.” Pharmacology, Biochemistry, and Behavior, vol. 213, Feb. 2022, p. 173321. EBSCOhost, https://doi.org/10.1016/j.pbb.2021.173321.

APA

Witkin, J. M., Lippa, A., Smith, J. L., Jin, X., Ping, X., Biggerstaff, A., Kivell, B. M., Knutson, D. E., Sharmin, D., Pandey, K. P., Mian, M. Y., Cook, J. M., & Cerne, R. (2022). The imidazodiazepine, KRM-II-81: An example of a newly emerging generation of GABAkines for neurological and psychiatric disorders. Pharmacology, Biochemistry, and Behavior, 213, 173321. https://doi.org/10.1016/j.pbb.2021.173321

Chicago

Witkin, Jeffrey M, Arnold Lippa, Jodi L Smith, Xiaoming Jin, Xingjie Ping, Andrew Biggerstaff, Bronwyn M Kivell, et al. 2022. “The Imidazodiazepine, KRM-II-81: An Example of a Newly Emerging Generation of GABAkines for Neurological and Psychiatric Disorders.” Pharmacology, Biochemistry, and Behavior 213 (February): 173321. doi:10.1016/j.pbb.2021.173321.